Femasys GAAP EPS of -$0.10, revenue of $729M
Source: SeekingAlpha
2025-11-14 17:15:28 ET
More on Femasys
- Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges
- Femasys stock falls after pricing capital raise of $8M via securities offering
- Seeking Alpha’s Quant Rating on Femasys
- Historical earnings data for Femasys
- Financial information for Femasys
Read the full article on Seeking Alpha
For further details see:
Femasys GAAP EPS of -$0.10, revenue of $729M
Femasys Inc.
NASDAQ: FEMY
FEMY Trading
5.14% G/L:
$0.5683 Last:
315,784 Volume:
$0.5469 Open:
FEMY Latest News
March 10, 2026 09:00:00 am
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
February 27, 2026 05:26:33 pm
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 26, 2026 09:00:00 am
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
February 23, 2026 09:00:00 am
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
FEMY Stock Data
$30,640,480
52,635,340
0.17%
16
N/A
Medical Equipment & Supplies
Healthcare
US
Suwanee
